Sign Out
Use in Renal Insufficient Patients: The pharmacokinetics of Rifaximin in patients with impaired renal function has not been studied.
Use in Hepatic Insufficient Patients: No dosage adjustment with Rifaximin is necessary due to its limited systemic absorption. Nonetheless, caution should be exercised when Rifaximin is administered to patients with severe hepatic impairment.
Use in Children: The safety and effectiveness of Hepaximin 550 mg for hepatic encephalopathy have not been established in patients <18 years of age.
Geriatric Use: Clinical studies of Hepaximin tablets did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently than younger subjects.
